Shares of Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) have been assigned an average rating of “Reduce” from the five ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $1.00.
A number of equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a report on Tuesday, August 18th.
Read Our Latest Stock Analysis on Traws Pharma
Traws Pharma Stock Down 8.4%
TRAW opened at $0.37 on Friday. The firm has a market cap of $5.68 million, a PE ratio of -0.21 and a beta of 1.52. The business has a fifty day simple moving average of $0.53 and a 200-day simple moving average of $0.93. Traws Pharma has a fifty-two week low of $0.36 and a fifty-two week high of $3.23.
Traws Pharma (NASDAQ:TRAW – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. On average, equities research analysts anticipate that Traws Pharma will post -1.20 EPS for the current fiscal year.
About Traws Pharma
Traws Pharma, Inc (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing medicines for viral infections and cancer. The company’s research and development programs are focused primarily on oral antiviral therapies for respiratory viruses, including influenza and COVID-19.
Traws Pharma’s antiviral pipeline includes tivoxavir marboxil, an investigational treatment designed to inhibit viral replication in influenza A, along with additional antiviral candidates targeting respiratory infections.
Further Reading
- Five stocks we like better than Traws Pharma
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
